Cover Image
市場調查報告書

美國的減肥藥、設備市場

U.S. Markets for Obesity Drugs & Devices

出版商 Medtech Insight 商品編碼 143932
出版日期 內容資訊 英文 176 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
美國的減肥藥、設備市場 U.S. Markets for Obesity Drugs & Devices
出版日期: 2015年02月27日 內容資訊: 英文 176 Pages
簡介

根據National Health and Nutrition Examination Survey (NHANES) ,在2012年中,美國的20歲以上的成人約35%,或約3分之一,分類到BMI (身體質量指數) 30kg/m2以上的肥胖。這換算起來相當於1億人以上的肥胖人口。在2014年中,美國的「新興」減肥藥及 (微創醫療) 設備市場規模的總合推算約3億7,470萬美元。預測期間,市場預計以年複合成長率32.4%,兩位數穩定成長,規模從2015年的4億5,540萬美元,到2020年擴大到18億5,210萬美元。

本報告提供美國的減肥藥、設備市場趨勢分析、主要的治療藥市場分析、各產品類型的市場分析,及新興醫療設備技術的分析。

摘要整理

第1章 減肥藥

  • 主要的減肥藥
    • Genentech/Roche Group (Xenical)
    • Vivus (Qsymia)
    • Arena Pharmaceuticals/Eisai (Belviq)
    • Orexigen Therapeutics/Takeda (Contrave)
  • 新興減肥藥
    • Gelesis (Gelesis100)
    • Hanmi Pharmaceuticals (LAPS CA-Exendin-4/HPP4404)
    • Novo Nordisk (Saxenda)
    • Orexigen Therapeutics (Empatic)
    • Rhythm Pharmaceuticals (RM-493)
    • Zafgen (Beloranib)
  • 市場分析
    • 市場預測
    • 競爭分析

第2章 腹腔鏡可調節胃束帶系統 (LAGB設備)

  • 主要的LAGB系統
    • Apollo Endosurgery
    • Ethicon Endo-Surgery/Johnson & Johnson
    • 其他LAGB設備
  • 市場分析
    • 手術數的預測
    • 市場預測
    • 競爭分析

第3章 胃水球設備

  • Apollo Endosurgery
  • Helioscopie
  • ReShape Medical
  • Spatz FGIA
  • Obalon Therapeutics
  • 市場分析

第4章 植入式迷走神經隔斷療法

  • EnteroMedics
  • MetaCure
  • 市場分析

第5章 其他新興醫療設備技術

  • Aspire Bariatrics
  • BAROnova
  • EndoSphere, Inc.
  • GI Dynamics
  • Onciomed
  • Scientific Intake
  • TransEnterix
  • USGI Medical
  • 其他

美國的總減肥藥、設備市場

  • 新興減肥藥市場
  • 肥胖治療設備市場

附錄:企業清單

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: A153

According to National Health and Nutrition Examination Survey (NHANES), approximately 35%, or nearly one out of three adults age 20 years or older were classified as obese in 2012 (the latest available statistics) based on a BMI of 30 kg/m2 or greater. This translates to more than 100 million obese people in the U.S.- a staggering number. Obesity has become such as concern due to increasing prevalence and the rise of serious health-related co-morbidities, such as type 2 diabetes, that it has recently been recognized by the American Medical Association, as well as other medical and government organizations, as a chronic disease. Due to the fact that type 2 diabetes and obesity are closely linked, the rise of obesity is increasing the prevalence of diabetes, making it critical to develop improved medical treatments to more effectively treat both conditions.

The fact that the overweight, obese and morbidly obese population remains vastly undertreated (in the U.S. and worldwide) bodes very well for next-generation obesity drugs and devices, as it leaves significant room for companies to profit and grow revenues in the coming decade in a virtually untapped U.S. market, expected to be valued at more than $1.8 billion by the year 2020.

This dynamic, new report from Medtech Insight includes analyses of selected products, current/forecast markets, surgical procedure volumes, competitors, market share by supplier, and opportunities in the U.S. Obesity Drugs and Devices Market. Specifically, this report covers leading and emerging prescription-based weight loss (obesity) drugs, and minimally invasive medical devices, including: laparoscopic adjustable gastric banding (LAGB) systems, intragastric balloon systems, implantable gastric stimulation devices, and other emerging device-based technologies, including nonsurgical/incisionless, transorally inserted or next-generation minimally invasive weight loss device therapies.

In 2014, the total, combined U.S. market for “new” obesity drugs and (minimally invasive medical) devices for the treatment of obesity was estimated at approximately $374.7 million. Over the forecast period, the total market is expected to advance at a healthy, double-digit compound annual rate of 32.4%, from an estimated $455.4 million in 2015 to an estimated $1,852.1 million in the year 2020.

Table of Contents

EXECUTIVE SUMMARY

  • i. U.S. Obesity Drugs & Devices Market
  • ii. Methodology
  • Exhibit ES-1: U.S. Obesity Drugs & Devices Market, 2013-2020

1. OBESITY DRUGS

  • 1.1. Leading Obesity Drugs
    • 1.1.1. Genentech/Roche Group (Xenical)
    • 1.1.2. Vivus (Qsymia)
    • 1.1.3. Arena Pharmaceuticals/Eisai (Belviq)
    • 1.1.4. Orexigen Therapeutics/Takeda (Contrave)
  • 1.2. Emerging Obesity Drugs
    • 1.2.1. Gelesis (Gelesis100)
    • 1.2.2. Hanmi Pharmaceuticals (LAPS CA-Exendin-4/HPP4404)
    • 1.2.3. Novo Nordisk (Saxenda)
      • 1.2.3.1. Victoza (liraglutide)
    • 1.2.4. Orexigen Therapeutics (Empatic)
    • 1.2.5. Rhythm Pharmaceuticals (RM-493)
    • 1.2.6. Zafgen (Beloranib)
  • 1.3. Market Analysis
    • 1.3.1. Market Forecast
      • 1.3.1.1. Market Drivers
      • 1.3.1.2. Market Limiters
    • 1.3.2. Competitive Analysis
  • Exhibit 1-1: 2015, FDA Approved Obesity Drugs
  • Exhibit 1-2: Xenical, SWOT Analysis
  • Exhibit 1-3: Qsymia, SWOT Analysis
  • Exhibit 1-4: Belviq, SWOT Analysis
  • Exhibit 1-5: Contrave, SWOT Analysis
  • Exhibit 1-6: 2015, Selected Obesity Drugs Recently FDA Approved or Under Development
  • Exhibit 1-7: Gelesis100 Mechanism of Action
  • Exhibit 1-8: New Obesity Drugs, Market Forecast, 2013-2020
  • Exhibit 1-9: 2013, New Obesity Drugs Market, Share by Supplier
  • Exhibit 1-10: 2014, New Obesity Drugs Market, Share by Supplier

2. LAPAROSCOPIC ADJUSTABLE GASTRIC BANDING SYSTEMS

  • 2.1. Leading LAGB Systems
    • 2.1.1. Apollo Endosurgery
    • 2.1.2. Ethicon Endo-Surgery/Johnson & Johnson
    • 2.1.3. Other LAGB Systems (Available Outside the U.S.)
      • 2.1.3.1. Agency for Medical Innovations
      • 2.1.3.2. Cousin Biotech
      • 2.1.3.3. Hélioscopie
      • 2.1.3.4. Médical Innovation Développement
  • 2.2. Market Analysis
    • 2.2.1. Procedure Volumes Forecast
    • 2.2.2. Market Forecast
      • 2.2.2.1. Market Drivers
      • 2.2.3.2. Market Limiters
    • 2.2.3. Competitive Analysis
  • Exhibit 2-1: Risks Associated with Gastric Banding and Abdominal/Bariatric Surgery
  • Exhibit 2-2: 2015, Laparoscopic Adjustable Gastric Banding Systems
  • Exhibit 2-3: Apollo EndoSurgery's LAP-BAND
  • Exhibit 2-4: Key Benefits and Risks of the LAP-BAND Procedure
  • Exhibit 2-5: Excess Weight Loss with the LAP-BAND System Compared to Roux-en-Y Gastric Bypass at 3 Years and Beyond
  • Exhibit 2-6: Ethicon Endo-Surgery's Curved Adjustable Gastric Endo Band, Features and Benefits
  • Exhibit 2-7: Comparison of Gastric Banding, Gastric Bypass, and Sleeve Gastrectomy
  • Exhibit 2-8: Agency for Medical Innovations'Soft Gastric Band Premium
  • Exhibit 2-9: Cousin Biotech's Bioring Adjustable Gastric Band
  • Exhibit 2-10: Hélioscopie's Heliogast HAGA Adjustable Gastric Band
  • Exhibit 2-11: Médical Innovation Développement's MIDBAND Adjustable Gastric Band
  • Exhibit 2-12: Laparoscopic Adjustable Gastric Banding, Procedure Volumes Forecast, 2013-2020
  • Exhibit 2-13: Estimated Number of Bariatric Surgeries, U.S. Procedure Volumes Forecast, 2013-2020
  • Exhibit 2-14: 2015 and 2020, Comparison of Estimated Bariatric Surgical Volumes, by Percentage and Type of Surgery
  • Exhibit 2-15: Laparoscopic Adjustable Gastric Banding, Market Forecast, 2013-2020
  • Exhibit 2-16: 2013, Laparoscopic Adjustable Gastric Banding Systems, Share by Supplier
  • Exhibit 2-17: 2014, Laparoscopic Adjustable Gastric Banding Systems Market, Share by Supplier

3. INTRAGASTRIC BALLOON SYSTEMS

  • 3.1. Apollo Endosurgery
  • 3.2. Hélioscopie
  • 3.3. ReShape Medical
  • 3.4. Spatz FGIA
  • 3.5. Obalon Therapeutics
  • 3.6. Market Analysis
    • 3.6.1. Market Drivers
    • 3.6.2. Market Limiters
  • Exhibit 3-1: Apollo Endosurgery's Orbera Managed Weight Loss System
  • Exhibit 3-2: Hélioscopie's Heliosphere Intragastric Balloon
  • Exhibit 3-3: ReShape Duo Intragastric Balloon System
  • Exhibit 3-4: REDUCE Pivotal Trial Results
  • Exhibit 3-5: The Spatz Adjustable Balloon System
  • Exhibit 3-6: Risks of Intragastric Balloon Placement
  • Exhibit 3-7: The Spatz Adjustable Balloon Procedure
  • Exhibit 3-8: The Obalon Gastric Balloon System Features and Possible Complications
  • Exhibit 3-9: Intragastric Balloon Therapy, Procedure Volumes Forecast, 2015-2020
  • Exhibit 3-10: Intragastric Balloon Systems, Market Forecast, 2015-2020

4. IMPLANTABLE VAGAL BLOCKING THERAPY

  • 4.1. EnteroMedics
  • 4.2. MetaCure
  • 4.3. Market Analysis
    • 4.3.1. Market Drivers
    • 4.3.2. Market Limiters
  • Exhibit 4-1: 2015, Implantable Pulse Generators Developed for the of Obesity
  • Exhibit 4-2: EnteroMedics' Maestro System
  • Exhibit 4-3: Overview of EnteroMedics' VBLOC Therapy and Vagus Nerve Function
  • Exhibit 4-4: Potential Benefits and Risks of VBLOC Therapy
  • Exhibit 4-5: Comparison of VBLOC Therapy, Laparoscopic Banding, and Gastric Bypass
  • Exhibit 4-6: MetaCure's DIAMOND (TANTALUS) Gastric Stimulation System
  • Exhibit 4-7: Implantable VBLOC Therapy Devices, EnteroMedics,Procedure Volumes Forecast, 2015-2020
  • Exhibit 4-8: Implantable VBLOC Therapy Devices, EnteroMedics, Market Forecast, 2015-2020

5. OTHER EMERGING MEDICAL DEVICE TECHNOLOGIES

  • 5.1. Aspire Bariatrics
  • 5.2. BAROnova
  • 5.3. EndoSphere, Inc.
  • 5.4. GI Dynamics
  • 5.5. Onciomed
  • 5.6. Scientific Intake
  • 5.7. TransEnterix
  • 5.9. USGI Medical
  • 5.9. Others
  • Exhibit 5-1: 2015, Selected Emerging Medical Device Technologies for the Treatment of Obesity
  • Exhibit 5-2: Aspire Bariatric's AspireAssist
  • Exhibit 5-3: EndoSphere's SatiSphere
  • Exhibit 5-4: GI Dynamic's EndoBarrier Gastrointestinal Liner and Procedure
  • Exhibit 5-5: Scientific Intake's SMART Device
  • Exhibit 5-6: USGI Medical's Incisionless Operating Platform
  • Exhibit 5-7: Primary Obesity Surgery, Endolumenal

TOTAL U.S. OBESITY DRUGS AND DEVICES MARKET

  • i. New Obesity Drugs Market
  • ii. Obesity Devices Market
  • Exhibit 6-1: U.S. Obesity Drugs & Devices Market, 2013-2020
  • Exhibit 6-2: U.S. New Obesity Drugs Market, 2013-2020
  • Exhibit 6-3: U.S. Obesity Devices Market, 2013-2020

APPENDIX: COMPANY LISTING

Back to Top